By Fineline Cube 
China-based Grand Pharmaceutical Group Co., Ltd. (HKG: 0512) announced that its subsidiary Chengdu Shetai Medical Technology Co., Ltd. has entered into a commercial cooperation agreement with Sirtex Medical US Holdings, Inc. (NASDAQ: SRX). The agreement ushers in a new phase of collaboration between the two companies.
Partnership Overview
The three-year partnership involves an annual expense of USD 12 million and will be centered on the research and development of medical device and radiopharmaceutical products. This strategic alliance aims to leverage the expertise and resources of both companies to drive innovation in the medical field.
Grand Pharmaceutical Group’s Vision
Grand Pharmaceutical Group has consistently been dedicated to advancing the research, production, and sales of high-quality generic chemical drugs and the development of innovative drugs. The group actively expands into the biomedical field and establishes strategic partnerships with enterprises globally to strengthen its competitiveness and innovation capabilities.
Sirtex Medical’s Mission
Sirtex Medical is committed to enhancing patient care by providing innovative treatments for liver cancer. The company focuses on developing, manufacturing, and commercializing life-saving medical products for the global market.-Fineline Info & Tech